Brief: Pepgen Announces Clearance By Health Canada Of CTA For PGN-Edo51 To Begin The Phase 2 Clinical Trial

PepGen

18/05/2023 12:03

May 18 (Reuters) - PepGen Inc  PEPG.O :
    * PEPGEN ANNOUNCES CLEARANCE BY HEALTH CANADA OF CTA FOR
PGN-EDO51
TO BEGIN THE PHASE 2 CLINICAL TRIAL, CONNECT1-EDO51, FOR THE
TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
    * PEPGEN INC - NITIAL DATA READOUT IS EXPECTED MID-2024
    * PEPGEN INC - EXPECTS TO BEGIN DOSING PATIENTS WITH
PGN-EDO51 IN
2H 2023
    * PEPGEN INC - PHASE 2 STUDY WILL EVALUATE SAFETY,
TOLERABILITY,
DYSTROPHIN LEVELS, PHARMACOKINETICS AND CLINICAL ASSESSMENTS

Source text for Eikon:  ID:nGNX5vjbpz 
Further company coverage:  PEPG.O